The American Journal of Managed Care

Multiple Pegfilgrastim Administration Options Allow for Patient-Centric Model of Care

With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require ...
MPR

Bone Pain Reduced With Pegfilgrastim Administration 72 Hours After Chemo

HealthDay News — For patients with breast cancer, administration of pegfilgrastim 72 hours postchemotherapy reduces pegfilgrastim-induced bone pain (PIBP) compared with administration at 24 and 48 ...
Medscape

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe ...
Business Insider

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

– Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgrastim – REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- ...
ascopubs.org

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results ...

To compare data on severe (grade 4) neutropenia duration and febrile neutropenia incidence in patients receiving chemotherapy with pegfilgrastim administered the same day or 24 hours after ...
Business Wire

Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend ® (pegfilgrastim - fpgk)

Provides accessible, high-quality treatment option for U.S. cancer patients undergoing chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia Broadens the company’s ...
Nasdaq

Cigna Study Published in Journal of Clinical Pathways Finds Home Infusions Improve Clinical Outcomes, Lower Costs

BLOOMFIELD, Conn., June 13, 2023 /PRNewswire/ -- A new study by Cigna Healthcare found that site-of-care redirection is associated with favorable clinical outcomes and increased access and ...
Business Wire

Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar ...
Seeking Alpha

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), a commercial-stage biopharmaceutical company focused on the research, development and commercialization of ...